Manufacturing

GSK's Arexvy RSV Vaccine: Efficacy Insights Over Three-Year Period
Management & Regulatory GSK's Arexvy RSV Vaccine: Efficacy Insights Over Three-Year Period

The landscape of respiratory syncytial virus (RSV) vaccination has seen significant developments with GSK's Arexvy vaccine leading the charge. Dive deep into the three-year efficacy data released by GSK, and understand what it means for the future of RSV vaccination, market dynamics, and

October 9, 2024
Is Your Viral Vector Testing Strategy Meeting These 7 Critical Steps?
Management & Regulatory Is Your Viral Vector Testing Strategy Meeting These 7 Critical Steps?

The market for gene therapies is predicted to surge from $9 billion in 2023 to $23.9 billion in 2028, according to MarketsandMarkets. With such rapid growth, it has become increasingly evident that having an effective analytical testing strategy is crucial for the successful development and

October 8, 2024
How Will Simtra's $14M Expansion Revolutionize ADC Manufacturing?
Management & Regulatory How Will Simtra's $14M Expansion Revolutionize ADC Manufacturing?

In a significant move to bolster its service offerings, Simtra BioPharma Solutions has announced a $14 million investment aimed at enhancing its Antibody-Drug Conjugates (ADCs) development and manufacturing capabilities. Set to establish a new clinical suite at its Halle/Westfalen, Germany site,

October 8, 2024
BioHub Maryland Receives Grant to Train Biopharma Workforce
Management & Regulatory BioHub Maryland Receives Grant to Train Biopharma Workforce

BioHub Maryland recently announced a significant development in its mission to bolster the biopharma workforce within the state. Securing a $75,000 grant under the EARN Maryland program, an initiative supported by the Maryland Department of Labor, the organization will use these funds to train

October 8, 2024
Eli Lilly's $4.5B Medicine Foundry to Boost Drug Production by 2027
Management & Regulatory Eli Lilly's $4.5B Medicine Foundry to Boost Drug Production by 2027

Eli Lilly's continued advancements in pharmaceutical innovation and their commitment to escalating manufacturing capabilities encapsulate the core of the company's recent endeavors. At the heart of these developments is Eli Lilly’s extensive investment in research and development and the s

October 3, 2024
J&J Invests Over $2B in North Carolina Biologics Plant, Adding 420 Jobs
Management & Regulatory J&J Invests Over $2B in North Carolina Biologics Plant, Adding 420 Jobs

Johnson & Johnson (J&J) has announced plans to construct a state-of-the-art biologics plant in Wilson, North Carolina, with construction set to commence in the first half of 2025. This ambitious project comes with a substantial investment exceeding $2 billion, aimed at bolstering

October 2, 2024
Loading

Subscribe to our weekly news digest!

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for subscribing.
We'll be sending you our best soon.
Something went wrong, please try again later